In summary, our findings revealed that the p53-miR-18-HSF2-IGF-IIR pathway controlled cardiomyopathy in the heart in vitro and in vivo, implying the therapeutic potential of miR-18 for the control of cardiac functions during hypertension-induced heart failure. Here, HSF2 is linked to cardiomyopathy.